<DOC>
	<DOCNO>NCT00000806</DOCNO>
	<brief_summary>PRIMARY : To evaluate safety , tolerability , pharmacokinetics , ethanol exposure two dose regimen formulation SC-52151 . SECONDARY : To evaluate preliminary anti-HIV activity treatment regimen relationship day 14 plasma concentration SC-52151 immunological virological marker toxicity . Since viral isolates decrease susceptibility protease inhibitor SC-52151 occur vitro multiple passage , since prolong post infectious effect occur vitro , comparison two formulation , elixir self-emulsifying drug delivery system ( SEDDS ) , need determine appropriate dose formulation Phase II study .</brief_summary>
	<brief_title>A Phase I Randomized Dose/Formulation Comparison Study SC-52151</brief_title>
	<detailed_description>Since viral isolates decrease susceptibility protease inhibitor SC-52151 occur vitro multiple passage , since prolong post infectious effect occur vitro , comparison two formulation , elixir self-emulsifying drug delivery system ( SEDDS ) , need determine appropriate dose formulation Phase II study . Patients randomize four treatment arm receive SC-52151 elixir SEDDS formulation 1 2 dos 2 week , follow-up 14 day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required patient CD4 count &lt; = 200 cells/mm3 : PCP prophylaxis use TMP/SMX aerosolized pentamidine . Allowed : Topical antifungal agent . Up 1000 mg/day acyclovir maintenance therapy herpes simplex virus . Antibiotics bacterial infection . Antipyretics , analgesic , nonsteroidal antiinflammatory agent , antiemetic , methadone symptomatic treatment . Patients must : HIV infection . CD4 count 150 500 cells/mm3 . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Unable tolerate standard diet require study . Unable give inform consent . Concurrent Medication : Excluded : Antiretrovirals biologic response modifier ( include HIV vaccine ) . Maintenance ketoconazole , fluconazole , itraconazole , ganciclovir , foscarnet , pyrimethamine , sulfadiazine , clindamycin , azithromycin , isoniazid , rifampin , rifabutin , ethambutol , pyrazinamide , clofazimine , clarithromycin . Prophylaxis Mycobacterial infection fungal infection Candidiasis . Allopurinol . Omeprazole . Astemizole . Terfenadine . Loratadine . Psychotropics . Phenylbutazone . Barbiturates . Benzodiazepines . Monoamine oxidase inhibitor . H2 blocker . Anticonvulsants . Coumadin anticoagulant . Oral contraceptive . Antiarrhythmics . Diltiazem . Metronidazole . Erythromycin . Chloramphenicol . Fluoroquinolones . Disulfiram . Erythropoietin . GCSF GMCSF . Systemic corticosteroid . Alcohol , include alcoholcontaining medication . Patients follow prior condition exclude : Unexplained temperature &gt; = 38.5 C 7 day within 30 day prior study entry . Chronic diarrhea ( &gt; = three stool per day ) 15 day within 30 day prior study entry . Malignancy basal squamous cell carcinoma skin , cervical intraepithelial neoplasia , minimal Kaposi 's sarcoma . Prior Medication : Excluded time : Prior HIV protease inhibitor . Excluded within 30 day prior study entry : Investigational drug . Recombinant erythropoietin . GCSF GMCSF . Interferon interleukin . Any HIV1 vaccine . Excluded within 14 day prior study entry : Antiretrovirals . Acute therapy opportunistic serious infection . Therapy malignancy . Maintenance ketoconazole , fluconazole , itraconazole , ganciclovir , foscarnet , pyrimethamine , sulfadiazine , clindamycin , azithromycin , isoniazid , rifampin , rifabutin , ethambutol , pyrazinamide , clofazimine , clarithromycin . Prophylaxis Mycobacterial infection fungal infection Candidiasis . Excluded within 7 day prior study entry : Allopurinol . Omeprazole . Astemizole . Terfenadine . Loratadine . Psychotropics . Phenylbutazone . Barbiturates . Benzodiazepines . Monoamine oxidase inhibitor . H2 blocker . Anticonvulsants . Coumadin anticoagulant . Oral contraceptive . Antiarrhythmics . Diltiazem . Metronidazole . Erythromycin . Chloramphenicol . Fluoroquinolones . Disulfiram . Risk Behavior : Excluded : History substance alcohol abuse . Ingestion 50 g alcohol daily within 6 month prior study entry . Recovered alcoholic .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1995</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
</DOC>